EdgeMarket › What Novo Holdings A/S reported owning
What Novo Holdings A/S reported owning
As filed on Form 13F for the quarter ending 2026-03-31, up to 45 days after that date. Long-only US-listed equity — shorts, bonds, cash and non-US listings are not on the form, so this is one leg of the book, not the book.
Reported value
1.2BPositions
22Quarter
2026-03-31Shown below
22largest by value
| holding | value | % of book | shares | price | 1y |
|---|---|---|---|---|---|
| EWTX Edgewise Therapeutics, Inc. | 168.5M | 13.7% | 5.3M | 44.18 | +219.2% |
| BN BROOKFIELD Corp /ON/ | 141.5M | 11.5% | 3.5M | 41.69 | -2.4% |
| ASML ASML HOLDING NV | 125.4M | 10.2% | 94.9K | 1,763.76 | +135.3% |
| MIRM Mirum Pharmaceuticals, Inc. | 122.4M | 9.9% | 1.3M | 96.31 | +44.4% |
| MPLT MapLight Therapeutics, Inc. | 74.9M | 6.1% | 3.7M | 11.21 | — |
| CRM Salesforce, Inc. | 73.4M | 5.9% | 393.2K | 209.17 | -15.1% |
| CRNX Crinetics Pharmaceuticals, Inc. | 56.3M | 4.6% | 1.6M | 84.69 | +191.1% |
| ELVN Enliven Therapeutics, Inc. | 50.2M | 4.1% | 1.3M | 59.82 | +204.3% |
| PCVX Vaxcyte, Inc. | 50.0M | 4.0% | 860.0K | 62.62 | +100.3% |
| PHVS Pharvaris N.V. | 49.4M | 4.0% | 1.8M | 36.27 | +57.7% |
| AVBP ArriVent BioPharma, Inc. | 44.8M | 3.6% | 1.9M | 29.12 | +51.1% |
| VRDN Viridian Therapeutics, Inc.\DE | 39.1M | 3.2% | 2.0M | 24.29 | +33.9% |
| CLDX Celldex Therapeutics, Inc. | 38.1M | 3.1% | 1.2M | 40.38 | +93.3% |
| APGE Apogee Therapeutics, Inc. | 37.9M | 3.1% | 450.0K | 134.75 | +274.1% |
| BMRN BIOMARIN PHARMACEUTICAL INC | 37.3M | 3.0% | 660.0K | 66.70 | +15.1% |
| FDMT 4D Molecular Therapeutics, Inc. | 34.0M | 2.8% | 3.7M | 15.83 | +131.1% |
| BABA Alibaba Group Holding Ltd | 32.3M | 2.6% | 257.3K | 119.34 | -0.1% |
| XENE Xenon Pharmaceuticals Inc. | 28.2M | 2.3% | 485.4K | 60.77 | +61.5% |
| BBOT BridgeBio Oncology Therapeutics, Inc. | 19.6M | 1.6% | 2.2M | 9.08 | -5.7% |
| VALN Valneva SE | 6.6M | 0.5% | 1.1M | 6.96 | -39.5% |
| LNZA LanzaTech Global, Inc. | 2.5M | 0.2% | 158.1K | 6.25 | -73.2% |
| MQ Marqeta, Inc. | 1.8M | 0.1% | 441.6K | 16.36 | -31.6% |
A position that grew quarter on quarter may simply reflect a higher price: if the stock rose 40% and the manager did nothing, the reported value rose 40%. Reading that as accumulation is reading the price back to yourself. More on that →
The whole archive is one click away.
Screener, filings, insider flow, backtests and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →